The role of the European Medicines Agency (EMA) is being reinforced, as the EU is increasing its powers to monitor drug development in times of crisis. ”A stronger EMA means that we can count on a coordinated EU response in mitigating and preventing medicine and medical devices shortages,” EU officials say.
BY PETER THOMSEN EU CORRESPONDENT FOR WATCH MEDIER, TRANSLATED BY DANIEL PEDERSEN
Soon, the European Medicines Agency (EMA) will have more power to oversee European drugmaking.
All of Medtech firm Ambu’s products already live up to the new EU rules for medical devices, something the firm attributes to a good sense of how much effort living up to the new legislation would require.
Expres2ion CEO Bent U. Frandsen is one of 3,000 volunteers participating in a phase III trial of Bavarian Nordic’s Covid-19 booster candidate. If the vaccine reaches the market, Expres2ion will be entitled to royalties.